מדד נזילות מהירה MIRA Pharmaceuticals (MIRA)

The available price action vector for MIRA Pharmaceuticals (MIRA) demonstrates metrics at the level of 202.65. The biotech firm develops synthetic cannabinoid substitutes to combat anxiety and neurological pathologies. Current capital is based on investments in the development of safe treatments for neuropathic pain. The company is currently focused on the scientific battle for patents, which shields it from direct price competition in the commercial market.

Quick liquidity measures a company's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding low-liquidity inventories. An acid-test liquidity analysis allows for an assessment of the financial stability of MIRA Pharmaceuticals (MIRA) amidst a high burn rate and early-stage drug development risks, revealing the actual capital cushion available before the commencement of clinical trials.